Differences in Drug-Susceptibility Patterns between Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium chimaera Clinical Isolates: Prospective 8.5-Year Analysis by Three Laboratories
Por:
Fernandez-Pittol M, Batista-Arnau S, Román A, San Nicolás L, Oliver L, González-Moreno O, Martínez JA, Amaro-Rodríguez R, Soler N, Gene-Giralt A, Gonzalez-Cuevas MA, Tudó G and Gonzalez-Martin J
Publicada:
1 ene 2023
Resumen:
Background: It has been suggested that Mycobacterium avium, Mycobacterium intracellulare, and M. chimaera have differential drug susceptibility patterns. We prospectively analyzed and compared the drug susceptibility patterns among these species over an 8.5-year period. Methods: A microdilution method (Slomyco((R))) was performed for drug susceptibility testing of 402 M. avium, 273 M. intracellulare, and 139 M. chimaera clinical isolates. Results: M. avium showed significantly higher resistance to moxifloxacin, ciprofloxacin, rifampicin, ethambutol, streptomycin, linezolid, cotrimoxazole, and clarithromycin. M. avium also showed higher minimum inhibitory concentrations (MIC) than M. intracellulare and M. chimaera against all drugs except ethionamide, to which M. intracellulare and M. chimaera showed greater resistance. Conclusions: Our series demonstrated differential drug resistance patterns among the most frequent M. avium complex species. M. avium was more resistant than M. intracellulare and M. chimaera versus eight antibiotics and showed greater MIC values to most of the antibiotics studied. These data suggest that knowledge of the local distribution and susceptibility profiles of these pathogens is essential for adequate clinical management.
Filiaciones:
Fernandez-Pittol M:
Servei de Microbiologia, CDB, Hospital Clínic de Barcelona, c/Villarroel 170, 08036 Barcelona, Spain
ISGLOBAL, Institute for Global Health, c/Rosselló 132, 08036 Barcelona, Spain
Batista-Arnau S:
ISGLOBAL, Institute for Global Health, c/Rosselló 132, 08036 Barcelona, Spain
Departament de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c/Casanova 143, 080036 Barcelona, Spain
Román A:
Servei de Microbiologia, CDB, Hospital Clínic de Barcelona, c/Villarroel 170, 08036 Barcelona, Spain
San Nicolás L:
Servei de Microbiologia, CDB, Hospital Clínic de Barcelona, c/Villarroel 170, 08036 Barcelona, Spain
Oliver L:
SYNLAB Diagnósticos Globales, Departamento de Microbiología y Parasitología, 08950 Esplugues de Llobregat, Spain
González-Moreno O:
SYNLAB Diagnósticos Globales, Departamento de Microbiología y Parasitología, 08950 Esplugues de Llobregat, Spain
Martínez JA:
Servei de Malalties Infeccioses, Hospital Clínic-Universitat de Barcelona, 08036 Barcelona, Spain
CIBER of Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain
Amaro-Rodríguez R:
Department of Pneumonology, Hospital Clínic-Universitat de Barcelona, 08036 Barcelona, Spain
Soler N:
Department of Pneumonology, Hospital Clínic-Universitat de Barcelona, 08036 Barcelona, Spain
Gene-Giralt A:
Laboratori, Hospital Sant Joan de Deu, 08950 Esplugues de Llobregat, Spain
Gonzalez-Cuevas MA:
Laboratori, Hospital Sant Joan de Deu, 08950 Esplugues de Llobregat, Spain
Tudó G:
Servei de Microbiologia, CDB, Hospital Clínic de Barcelona, c/Villarroel 170, 08036 Barcelona, Spain
ISGLOBAL, Institute for Global Health, c/Rosselló 132, 08036 Barcelona, Spain
Departament de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c/Casanova 143, 080036 Barcelona, Spain
Gonzalez-Martin J:
Servei de Microbiologia, CDB, Hospital Clínic de Barcelona, c/Villarroel 170, 08036 Barcelona, Spain
ISGLOBAL, Institute for Global Health, c/Rosselló 132, 08036 Barcelona, Spain
Departament de Fonaments Clínics, Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, c/Casanova 143, 080036 Barcelona, Spain
CIBER of Infectious Diseases (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain
Green Submitted, gold
|